Vesalius Biocapital leads €6.2m Omeicos series-A

Vesalius invested via its second fund. IBB Beteiligungsgesellschaft also invested from its VC Fonds Technologie Berlin vehicle, while High-Tech Gründerfonds (HTGF), and KfW Bank also committed to the round.

Life sciences-focused asset management company Ascenion also provided Omeicos with a €550,000 subsidy from its Spinnovator grant programme, which is backed by the German Ministry of Education and Research.

The fresh funding will be used to advance Omeicos's lead candidate in atrial fibrillation through pre-clinical trials into clinical development.

Atrial fibrillation is the most common type of heartbeat irregularity in humans and results in inefficient blood pumping, which increases the risk of stroke and heart failure. The market for treatment of the disease is expected to be worth around $9bn by 2020.

Company
Omeicos span out of the Max Delbrück Centre for Molecular Medicine in Berlin. It develops small-molecule therapeutics for the prevention and treatment of cardiovascular diseases, including atrial fibrillation. The company's planned lead candidate is an oral treatment to be taken once a day by patients with persistent atrial fibrillation in order to maintain a regular heartbeat.

People
Christian Schneider and Gaston Matthyssens worked on the deal for Vesalius Biocapital Partners. Ute Mercker represented IBB, while Martin Pfister is senior investment manager at HTGF. All four joined Omeicos co-founder Wolf-Hagen Schunck on the company's supervisory board. Robert Fischer is managing director of Omeicos.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds